Targeting CD47 as a Novel Immunotherapy for Breast Cancer

Can Chen; Runlu Wang; Xi Chen; Yulong Hou; Jingting Jiang

doi:10.3389/fonc.2022.924740

Targeting CD47 as a Novel Immunotherapy for Breast Cancer

Front Oncol. 2022 Jul 4:12:924740. doi: 10.3389/fonc.2022.924740. eCollection 2022.

Authors

Can Chen¹, Runlu Wang², Xi Chen³, Yulong Hou⁴, Jingting Jiang⁵

Affiliations

¹ Department of Oncology, The Third Affiliated Hospital of Soochow University, Changzhou, China.
² Respiratory Division, The Second Hospital of Hebei Medical University, Shijiazhuang, China.
³ Department of Dermatology, First People's Hospital, Huzhou, China.
⁴ Department of Surgery, Huzhou Central Hospital, Huzhou, China.
⁵ Department of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University, Changzhou, China.

Abstract

Nowadays, breast cancer has become the most common cancer worldwide with a high mortality rate. Immune checkpoint blockade holds great promise in tumor-targeted therapy, and CD47 blockade as one immune therapy is undergoing various preclinical studies and clinical trials to demonstrate its safety and efficacy in breast cancer. In this review, we summarized different therapeutic mechanisms targeting CD47 and its prognostic role and therapeutic value in breast cancer.

Keywords: CD47; SIRPα; breast cancer; immune checkpoint inhibitors; immunotherapy.

Publication types

Review